Page 4 - Thomas Theuringer News Today

Start of worldwide diagnostic use follows the launch of upgraded EZ2 Connect for research use in 2021, builds on the success of EZ1 Connect platform found in thousands of labs worldwide EZ2

Partnership to leverage the Helix Laboratory Platform powered by QIAGEN's biopharma relationships, NGS capabilities, and global regulatory expertise Addressing health burden in neuro-degenerative

therascreenKRAS RGQ PCR kit approved as a companion diagnostic to aid in identifying non-small cell lung cancer (NSCLC) patients eligible for treatment with KRAZATI (adagrasib) KRAS mutations

NeuMoDx MPXV Test Strip enables researchers to quickly identify both clade I II of the monkeypox virus Dual-target design to reduce false negatives Multiplex test strengthens QIAGEN's

Q3 2022: Net sales of $500 million (-7% at actual rates, 0% at constant exchange rates, CER); diluted EPS of $0.36 and adjusted diluted EPS of $0.53 Net sales at CER of $533 million vs.

Initial development and validation of clinical trial assay Next-generation sequencing (NGS) based assay targeting LRRK2 from blood samples Collaboration expands QIAGEN's NGS testing

Greenhouse gas emissions intensity lowered by 16% and plastic footprint down 9.6% vs. 2020 Commitment to ambitious climate goals: Net-zero by 2050, Scope 1 and 2 emissions down 42% by 2030

QIAstat-Dx Viral Vesicular Panel tests for six pathogens that produce similar symptoms Panel boosts global research and surveillance of monkeypox using gold-standard PCR technology QIAGEN

U.S. public health agency validated digital PCR technologies including QIAcuity as the way to reliably detect multiple disease targets in wastewater samples QIAcuity previously awarded U.S.

Dr. Eva Pisa proposed as a new member to the Supervisory Board, contributes significant leadership experience in Life Science and Molecular Diagnostics industry All seven current Supervisory